

# Supporting Information

Breshears et al. 10.1073/pnas.0909796107

## SI Materials and Methods

**Generation and Identification of *myoG* Null Mutants.** A *myoG* disruption plasmid was created by first PCR cloning 1.4 kb of the 5' region of the *myoG* gene (Dictybase Gene ID DDB\_G0276363; nts 2711–4093 of genomic sequence), and then inserting a blasticidin resistance cassette (1) into the internal Cla I site. The resulting pDTx4 plasmid was linearized and electrotransformed into Ax2 cells (2). Colonies selected for growth in blasticidin were screened for homologous recombination at the *myoG* locus by Southern analysis of genomic DNA digested with Apa LI using the Roche DIG system (Roche). A drug-resistant non-homologous recombinant (2-1; nonhomologous recombinants) that behaved identically to the parental Ax2 parental strain was isolated from the same transformation as HTD36-2 and used as a control for the experiments reported here.

**RNA Isolation and RT-PCR.** Bacterially grown early log-phase cells (i.e.,  $0.8\text{--}1.0 \times 10^6$  cells/mL) were washed into MMC, shaken at 150 rpm for 1 h and the pulsed to 100 nM cAMP for several hours while shaking. Total RNA was isolated from samples using TRIZOL (Invitrogen) at each time point. Oligo dT-primed cDNA was prepared using MuLV reverse transcriptase (New England Biolabs) and the following primer sets used for subsequent PCR:

*H7*: H7-S: 5'-ACGTTCAAACATAAATACGGAGCTGGT-3'  
H7-AS: 5'-TTTGAGTGGTTTGCCAATTTCTTTT-3'  
*carA*: *carA*-1S: 5'-GGTTGTATGGCAGTGTGATTGG-3'

*carA*-2AS: 5'-CAAATCTTTCTGGTTCTGGTTCTC-3';  
*aca4*: *aca*-3S: 5'-ATGGCGGTTTCAGGTTTAGATGG-3'  
*aca*-4AS: 5'-TGAGCCAATTTACCCAAGAGCG-3'.  
*myoG*: *myx57*: 5'-CAAAGAATGGGATGGCGTTGAAAG-3'  
*myx58*: 5'-CCTCAGAGATGATTGGAGTGTC-3'

The *H7* gene was used as an internal control for cDNA synthesis in the RT-PCR experiments as it is expressed at a constant level throughout development (3). No RT control reactions were performed to verify the absence of genomic DNA in each sample. The levels of cDNA used in each reaction was normalized by first performing PCR using *H7* primers and determining the volume of cDNA to obtain a similar level of product in each reaction. The numbers of cycles were varied for each primer pair to determine the number necessary to obtain detectable amounts of product without saturating the reaction.

**Localization of cAR1-GFP and CRAC-GFP.** Control or *myoG* mutant transformants expressing cAR1-GFP (4) or CRAC (cytosolic regulator of adenylate cyclase)-GFP (5) were maintained in HL5 supplemented with 10  $\mu\text{g}/\text{mL}$  G418 (Fisher Chemical). Aggregation competent CRAC-GFP-expressing cells were allowed to adhere to coverslips and treated with latrunculinA for 20 min before cAMP pulsing (5). cAMP was administered to a final concentration of 100 nM during the second frame of each movie. Movies were made for 45 s at 20 frames per minute. Images were obtained with a Zeiss Axiovert microscope and 63 $\times$  Plan-Apo, 1.4 NA oil-immersion lens.

1. Sutoh K (1993) A transformation vector for *Dictyostelium discoideum* with a new selectable marker bsr. *Plasmid* 30:150–154.  
2. Lee E, Shelden EA, Knecht DA (1998) Formation of F-actin aggregates in cells treated with actin stabilizing drugs. *Cell Motil Cytoskeleton* 39:122–133.  
3. de Chasse B, Dubois A, Lefkir Y, Letourneur F (2001) Identification of clathrin-adaptor medium chains in *Dictyostelium discoideum*: differential expression during development. *Gene* 262:115–122.

4. Xiao Z, Zhang N, Murphy DB, Devreotes PN (1997) Dynamic distribution of chemoattractant receptors in living cells during chemotaxis and persistent stimulation. *J Cell Biol* 139: 365–374.  
5. Parent CA, Blacklock BJ, Froehlich WM, Murphy DB, Devreotes PN (1998) G protein signaling events are activated at the leading edge of chemotactic cells. *Cell* 95:81–91.



